Mirzap 15 Tablet, a novel antidepressant medication, contains 15mg of Mirtazapine, a piperazinoazepine derivative. This orally administered agent is indicated for the treatment of major depressive disorder, particularly in patients who have not responded adequately to selective serotonin reuptake inhibitors (SSRIs) or other antidepressant therapies. Mirzap 15 Tablet exerts its therapeutic effects through a multifaceted mechanism of action, including the antagonism of alpha-1 and alpha-2 adrenergic receptors, blockade of 5-HT3 receptors, and augmentation of serotonin release. Its unique pharmacological profile enables it to address various aspects of depression, including mood, cognitive, and somatic symptoms. The tablet is designed for once-daily administration, allowing for a convenient and predictable dosing regimen. Common side effects may include sedation, dizziness, and increased appetite, although these often subside with continued treatment. As with any medication, patients should be carefully monitored for signs of increased suicidal ideation, particularly during the initial stages of therapy.